Reimbursement/ Market Access
The reimbursement of your medicinal products ensures the solvency of the market. Nevertheless, this decision remains the prerogative of each Member State of the EU.
WHITE-TILLET advises and assists you in:
- The preparation of the market access strategy (town/hospital);
- The critical analysis of your clinical data (methodology, comparators, level of evidence).
- The preparation of the reimbursement files for France (medico-technical files for the commission of transparency, economic efficiency for the CEESP, and economic file for the CEPS);
- The conventional negotiation for pricing with the CEPS;
- The preparation of platform files for Europe;
- The analysis of national situations in the EU via our European network.
Tillet Y. Medical Assessment of drugs and medical devices to be reimbursed: rules in vigor, impact of the new Bertrand law, new announced reforms. Gazette de l’AFAR 2012;75:28-34 (in French).
24 Rue Gambetta 77400 LAGNY-SUR-MARNE, France